medigraphic.com
Colegio de Medicina Interna de México.

2021, Number 5

<< Back Next >>

Med Int Mex 2021; 37 (5)

The evolution of pharmacological treatment of COVID-19

Del Carpio-Orantes L

Language: Spanish
References: 24
Page: 842-845
PDF size: 194.18 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Del Carpio-Orantes L. Del 2019-nCoV al COVID-19, caracterizando la enfermedad. Med Int Méx 2020; 36 (3): 414-417. https://doi.org/10.24245/mim.v36i3.4009.

  2. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID- 19): A review. JAMA 2020; 10.1001/jama.2020.6019. doi:10.1001/jama.2020.6019.

  3. Wu R, Wang L, Kuo HD, Shannar A, et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep 2020; 1-15. doi. 10.1007/s40495-020-00216-7.

  4. Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 2020; 370: m2980. doi. 10.1136/ bmj.m2980.

  5. Li H, Wang YM, Xu JY, Cao B. [Potential antiviral therapeutics for 2019 Novel Coronavirus]. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43 (3): 170-172. doi:10.3760/cma.j.is sn.1001-0939.2020.03.004.

  6. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178: 104787. doi:10.1016/j.antiviral.2020.104787.

  7. Schmith VD, Zhou JJ, Lohmer LRL. The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19. Clin Pharmacol Ther 2020; 10.1002/cpt.1889. doi:10.1002/cpt.1889.

  8. Pepperrell T, Pilkington V, Owen A, Wang J, Hill AM. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. J Virus Erad 2020; 6 (2): 52-60. doi:10.1016/S2055-6640(20)30017-0.

  9. Fadel R, Morrison AR, Vahia A, Smith Z, et al. Early short course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis 2020; ciaa601. doi:10.1093/cid/ciaa601.

  10. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19 - Preliminary report. N Engl J Med 2020; 10.1056/NEJMoa2021436. doi:10.1056/NEJMoa2021436.

  11. Porfidia A, Pola R. Venous thromboembolism in COVID-19 patients. J Thromb Haemost 2020; 18 (6): 1516-1517. doi:10.1111/jth.14842.

  12. Cattaneo M, Morici N. Is thromboprophylaxis with highdose enoxaparin really necessary for COVID-19 patients? A new “prudent” randomised clinical trial. Blood Transfus 2020; 18 (3): 237-238. doi:10.2450/2020.0109-20.

  13. Xu X, Han M, Li T, Sun W, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020; 117 (20): 10970-10975. doi:10.1073/ pnas.2005615117.

  14. Alzghari SK, Acuña VS. Supportive treatment with tocilizumab for COVID-19: A systematic review. J Clin Virol 2020; 127: 104380. doi. 10.1016/j.jcv.2020.104380

  15. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA). https://clinicaltrials.gov/ct2/show/NCT04320615.

  16. Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. https://www.roche.com/ investors/updates/inv-update-2020-07-29.htm

  17. A study to evaluate the efficacy and safety of remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized participants with severe COVID-19 pneumonia (REMDACTA). https://clinicaltrials.gov/ct2/show/ NCT04409262.

  18. EMPACTA trial. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia. https://clinicaltrials.gov/ct2/show/ NCT04372186.

  19. Grein J, Ohmagari N, Shin D, Diaz G, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382 (24): 2327-2336. doi. 10.1056/ NEJMoa2007016

  20. Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID- 19? J Antimicrob Chemother 2020; 75 (7): 2013-2014. doi:10.1093/jac/dkaa171.

  21. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect 2020; 81 (2): 318-356. doi:10.1016/j.jinf.2020.04.017.

  22. Seif F, Aazami H, Khoshmirsafa M, et al. JAK inhibition as a new treatment strategy for patients with COVID-19. Int Arch Allergy Immunol 2020; 181 (6): 467-475. doi:10.1159/000508247. 2020;181(6):467-475.

  23. Dimopoulos G, de Mast Q, Markou N, Theodorakopoulou M, et al. Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe 2020; 28 (1): 117-123.e1. doi:10.1016/j.chom.2020.05.007

  24. Seifirad S. Pirfenidone: A novel hypothetical treatment for COVID-19. Med Hypotheses 2020; 144: 110005. doi:10.1016/j.mehy.2020.110005.




2020     |     www.medigraphic.com